GXV-813
GXV-813, also known as EX-A8078, is a muscarinic acetylcholine M 4 receptor agonist which is under development for the treatment of schizophrenia.
≈ 1 min read
GXV-813. encyclopegia.org, snapshot enwiki-001372021107. /a/gxv-813
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
GXV-813, also known as EX-A8078, is a muscarinic acetylcholine M 4 receptor agonist which is under development for the treatment of schizophrenia. It is taken orally. The drug is under development by Novartis.
As of March 2026, it is in phase 2 clinical trials for schizophrenia. The drug also is or was under development for another unspecified indication, but no recent development for this use has been reported. Two phase 2 trials for schizophrenia are underway and expected to be completed in April 2027.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372021107 under CC BY-SA 4.0; modifications have been made.